VRPX Stock - Virpax Pharmaceuticals, Inc.
Unlock GoAI Insights for VRPX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-12,079,935,000 | $-15,689,788 | $-21,845,133 | $-12,025,500 | $-4,195,719 |
| Net Income | $-12,067,225,000 | $-15,189,508 | $-21,456,307 | $-12,148,885 | $-4,487,587 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2836.41 | $-12.97 | $-18.32 | $-10.37 | $-9.07 |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Visit WebsiteEarnings History & Surprises
VRPXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 12, 2025 | — | $-68.75 | — | — |
Q1 2025 | Mar 3, 2025 | $-0.27 | $-0.80 | -196.3% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.54 | $-10.75 | -1890.7% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-1.53 | $-43.75 | -2759.5% | ✗ MISS |
Q2 2024 | May 13, 2024 | — | $-68.75 | — | — |
Q1 2024 | Mar 26, 2024 | $-2.70 | $-3.90 | -44.4% | ✗ MISS |
Q4 2023 | Nov 15, 2023 | $-0.26 | $-127.50 | -48938.5% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-40.00 | $-67.50 | -68.8% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-75.00 | $-32.50 | +56.7% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-6.70 | $-65.00 | -870.1% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.45 | $-162.50 | -36011.1% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.44 | $-125.00 | -28309.1% | ✗ MISS |
Q2 2022 | May 16, 2022 | — | $-110.00 | — | — |
Q1 2022 | Mar 31, 2022 | $-3.40 | $-0.62 | +81.9% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | — | $-132.50 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-117.50 | — | — |
Q2 2021 | May 18, 2021 | $-0.54 | $-0.60 | -11.7% | ✗ MISS |
Q1 2021 | Mar 31, 2021 | — | $-0.16 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.38 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.26 | — | — |
Latest News
Frequently Asked Questions about VRPX
What is VRPX's current stock price?
What is the analyst price target for VRPX?
What sector is Virpax Pharmaceuticals, Inc. in?
What is VRPX's market cap?
Does VRPX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VRPX for comparison